Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes

OBJECTIVE: Assessment of the efficacy and safety of TAK-875 (a novel GPR40 agonist) in Japanese patients with type 2 diabetes inadequately controlled by diet/exercise. RESEARCH DESIGN AND METHODS: This was a phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled, 12-week...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Kohei, Araki, Takahiro, Yoshinaka, Ryoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554318/
https://www.ncbi.nlm.nih.gov/pubmed/23086138
http://dx.doi.org/10.2337/dc12-0872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554318/
https://www.ncbi.nlm.nih.gov/pubmed/23086138
http://dx.doi.org/10.2337/dc12-0872

Ejemplares similares